B+
Bull case
20%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
BIOA
BioAge LabsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-01 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-01
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+64.0
Score
AI commentary
Primary-source evidence is strong for the pipeline plan and financing, but forward visibility remains limited because trial-start execution and clinical efficacy are unconfirmed. Recent news flow is sparse and includes a negative July 31 headline; social and options evidence are unavailable. The deterministic prior remains negative for near- and medium-term returns, while peer comparability is limited, supporting cautious monitoring rather than a high-conviction bullish view.
RankAlpha Sentiment Codex - 2026-08-01
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31catalystNear-term sentiment and insider-sale overhangHigh impact
A Form 4 records two open-market sales by the principal accounting officer on June 29–30, with zero shares owned afterward [#SEC-FORM4-2026-07-01]. Sparse recent coverage also includes a negative July 31 headline, creating near-term pressure despite limited operating information.
2026-09-30eventConfirmation of BGE-102 trial executionHigh impact
The planned cardiovascular and diabetic-macular-edema proof-of-concept programs create near-term execution checkpoints. The packet does not confirm that planned mid-2026 starts occurred, so any delay could weigh on sentiment [#SEC-8K-2026-05-08].
2026-12-31eventBGE-102 cardiovascular proof-of-concept dataHigh impact
BioAge plans to initiate a Phase 2 dose-ranging trial in elevated cardiovascular risk, with topline data anticipated by year-end 2026. The program has positive Phase 1 biomarker and tolerability data, but clinical efficacy remains unproven [#SEC-8K-2026-05-08].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-01 • Updated nightlySource: Internal modelMethodology